12:19 PM EDT, 10/25/2024 (MT Newswires) -- Ocuphire Pharma (OCUP) acquired Opus Genetics and the combined company will operate as Opus Genetics, the Retinal Degeneration Fund said Friday.

The combined company will focus on developing gene therapies to cure genetic eye disorders and trade on the Nasdaq under the ticker "IRD", the RD Fund added.

Financial terms of the transaction were not disclosed.

Ocuphire Pharma shares were down 12% in recent trading.

Price: 1.17, Change: -0.16, Percent Change: -12.03